Marine Antimicrobial Peptides: Ocean's Pharmacy
Natural Source Antimicrobial Peptides
70+ AMP Candidates
Over 70 antimicrobial peptides derived from marine organisms are in various stages of drug development, with 42 currently in clinical trials worldwide.
Gao et al., Marine Drugs, 2025
Gao et al., Marine Drugs, 2025
View as imageThe ocean covers 71% of Earth's surface and contains organisms that have been producing antimicrobial peptides for hundreds of millions of years. Marine invertebrates lack the adaptive immune system that vertebrates rely on. Instead, they defend against pathogens with innate immune molecules, chief among them antimicrobial peptides (AMPs) that puncture bacterial membranes, disrupt biofilms, and even interfere with gene expression at the DNA level.[1]
This matters now because antibiotics are failing. Antimicrobial resistance (AMR) caused an estimated 4.95 million associated deaths globally in 2019, and the pipeline of new conventional antibiotics has slowed to a trickle. Marine-derived AMPs offer structurally distinct alternatives that kill bacteria through mechanisms fundamentally different from those of traditional antibiotics, making cross-resistance unlikely.[1] A 2025 review in Marine Drugs documented over 70 marine AMPs as drug candidates worldwide, with 42 in clinical trials targeting Gram-positive infections, fungal infections, diabetic foot ulcers, and burn wounds.[1]
This article surveys the full evidence landscape for marine antimicrobial peptides: which organisms produce them, how they work, and how close they are to becoming drugs. For related coverage of terrestrial AMPs, see our articles on frog skin peptides, insect antimicrobial peptides, and where AMPs come from across the animal kingdom.
Key Takeaways
- Over 70 marine-derived AMPs are in drug development, with 42 in clinical trials for infections including MRSA, fungal disease, and diabetic foot ulcers (Gao et al., Marine Drugs, 2025)
- A novel horseshoe crab peptide, CpAMP, showed broad-spectrum antibacterial activity against both Gram-positive and Gram-negative bacteria (Wang et al., Fish & Shellfish Immunology, 2025)
- Marine peptide N6NH2 from tilapia exhibited dual antibacterial and immunomodulatory function against multidrug-resistant Aeromonas veronii (Li et al., Fish & Shellfish Immunology, 2026)
- Genome mining of marine Streptomyces yielded peptides L3 and L3-K that kill bacteria by disrupting gene expression at the DNA level, not by membrane lysis (Beyer et al., ACS Infectious Diseases, 2026)
- Pengonadins, a newly described shrimp-specific AMP family, have up to four cysteine residues stabilizing their structure, expanding the known diversity of crustacean defense peptides (Matos et al., Fish & Shellfish Immunology, 2026)
- Modified tachyplesin I with N-terminal acetylation and C-terminal amidation showed altered cytotoxicity profiles, demonstrating how small chemical changes can tune marine AMP selectivity (Kuzmin et al., Bulletin of Experimental Biology and Medicine, 2017)
What Makes Marine AMPs Different
Marine organisms live in environments saturated with microbes. Seawater contains approximately 10 million viruses and one million bacteria per milliliter. Organisms that evolved in this soup, especially sessile invertebrates like sponges, tunicates, and mussels that cannot flee from pathogens, developed antimicrobial defenses of unusual potency and structural diversity.[2]
Several structural features distinguish marine AMPs from their terrestrial counterparts. Marine AMPs frequently contain unusual amino acids, post-translational modifications, and disulfide bond architectures not found in mammalian or amphibian peptides. The extreme pressures, temperatures, and salt concentrations of marine environments have selected for peptides with exceptional stability.[3]
Guryanova and Ovchinnikova (2025) catalogued the therapeutic activities of marine peptides beyond antimicrobial function: antibiofilm, antifungal, antiviral, antiparasitic, anticancer, immunomodulatory, and anti-inflammatory properties. Many marine AMPs are multifunctional molecules, killing pathogens directly while simultaneously activating the host immune response.[2]
The salt tolerance of marine AMPs is particularly relevant for clinical applications. Many mammalian AMPs lose activity at physiological salt concentrations (150 mM NaCl), which limits their therapeutic utility. Marine AMPs evolved in high-salt environments and retain activity under conditions that inactivate terrestrial peptides.[3]
Horseshoe Crabs: Where Marine AMP Research Began
Horseshoe crabs (Limulidae) are living fossils that have survived essentially unchanged for 450 million years, partly due to an extraordinarily effective innate immune system. Their hemocytes (blood cells) contain granules packed with antimicrobial peptides that are released upon pathogen detection.
Tachyplesin, first isolated from the hemocytes of Tachypleus tridentatus, is a 17-residue beta-hairpin peptide with a molecular weight of 2.36 kDa. It has two disulfide bonds that lock it into a rigid structure and C-terminal amidation that enhances its membrane-disrupting activity. Tachyplesin exhibits broad-spectrum activity against Gram-negative bacteria, Gram-positive bacteria, fungi, and viruses.[4]
Kuzmin et al. (2017) tested how N-terminal acetylation and C-terminal amidation alter tachyplesin I's cytotoxic properties. Using MTT assays, they found that these terminal modifications changed the peptide's selectivity between bacterial and mammalian cells. This is a critical finding for drug development: the same core structure can be tuned for different therapeutic windows by modifying its ends.[4]
Kumar and Chugh (2021) demonstrated that tachyplesin has activity beyond antibacterial defense. They tested it against Leishmania donovani, the parasite responsible for visceral leishmaniasis, a neglected tropical disease. Tachyplesin emerged as an effective anti-leishmanial agent, suggesting that the membrane-disrupting mechanism that kills bacteria can also target eukaryotic parasites.[5]
Wang et al. (2025) identified CpAMP, a novel antimicrobial peptide from the Chinese horseshoe crab, using transcriptome analysis. CpAMP showed broad-spectrum antibacterial activity against both Gram-positive and Gram-negative bacteria, expanding the known repertoire of horseshoe crab defense molecules. The study demonstrates that even well-studied organisms like horseshoe crabs still harbor undiscovered AMPs.[6]
Polyphemusins I and II, isolated from the American horseshoe crab Limulus polyphemus, are structurally related to tachyplesin but contain an additional arginine residue at the N-terminal that alters their charge distribution and antimicrobial spectrum. The two disulfide bonds in both tachyplesin and polyphemusin create a constrained beta-hairpin that resists unfolding in harsh environments, a structural strategy that marine AMPs use far more extensively than their terrestrial counterparts.
The horseshoe crab immune system also gave science one of its most important biomedical tools: the Limulus amebocyte lysate (LAL) test, used globally to detect bacterial endotoxin contamination in injectable drugs and medical devices. The same hemocyte granules that release tachyplesin also contain the coagulation cascade that forms the basis of the LAL assay. Horseshoe crab blood, harvested commercially for this purpose, underscores how marine immune chemistry has already shaped human medicine. For broader context on how these beta-hairpin peptides form pores in bacterial membranes, see our article on how antimicrobial peptides kill bacteria.
Shrimp, Fish, and Crabs: AMPs from Aquaculture Species
Aquaculture species face intense pathogen pressure in high-density farming environments, making them rich sources of novel AMPs. Research in this area is driven by both pharmaceutical discovery and the aquaculture industry's need for antibiotic alternatives.
Matos et al. (2026) described pengonadins, a newly identified penaeid shrimp-specific antimicrobial peptide family. Unlike the well-known anti-lipopolysaccharide factors (ALFs) that have two cysteine residues forming a single disulfide bond, pengonadins contain three or four cysteine residues, creating more complex structural architectures. This structural novelty expands the known diversity of crustacean defense peptides and provides new scaffolds for drug design.[7]
Lin et al. (2026) characterized LRSG08, an antimicrobial peptide from the Pacific white shrimp Penaeus vannamei, demonstrating antibacterial activity against Vibrio species. Vibrio pathogens cause both aquaculture losses and human infections worldwide, making AMP-based alternatives to antibiotics particularly valuable in this context.[8]
Li et al. (2026) demonstrated that the marine peptide N6NH2, derived from tilapia, has dual antibacterial and immunomodulatory function against multidrug-resistant (MDR) Aeromonas veronii. They also tested a D-enantiomer (mirror image) version of the peptide, which showed enhanced stability against proteolytic degradation while retaining antimicrobial potency. The D-enantiomer approach is a common strategy for extending peptide half-life in therapeutic applications.[9]
Bai et al. (2026) identified Boleokidin39-61, an antimicrobial peptide from an amphibious fish (a fish that can survive on land), with broad-spectrum antibacterial and anti-biofilm activity. The peptide's origin in a species that bridges aquatic and terrestrial environments is notable: it faces pathogen challenges from both ecosystems.[10]
Dong et al. (2025) addressed a practical manufacturing challenge by expressing the marine AMP Spgillcin177-189 (originally from the mud crab Scylla paramamosain) in the yeast Pichia pastoris using a multicopy expression strategy. The recombinant peptide showed strong antimicrobial activity against Staphylococcus aureus, demonstrating that marine AMPs can be produced at scale through biotechnology rather than extraction from source organisms.[11]
Cone Snails and Marine Invertebrates
Cone snails (genus Conus) produce some of the most pharmacologically active peptides found in nature. Their venom contains conotoxins, small disulfide-rich peptides that target ion channels and receptors with extraordinary specificity. While conotoxins are technically toxins rather than antimicrobial peptides, they illustrate the broader pharmacological potential of marine peptide chemistry.
Margiotta et al. (2022) reviewed conotoxins from Conus regius, documenting novel therapeutic opportunities including pain management, cardiovascular applications, and neurological targets. One conotoxin derivative, ziconotide (Prialt), is already FDA-approved for severe chronic pain, representing one of the few marine peptides to reach clinical use.[12]
Sponges, tunicates (sea squirts), and other sessile invertebrates are among the richest sources of marine AMPs. These organisms cannot flee from microbial threats and have invested heavily in chemical defense. Clavanins, isolated from the tunicate Styela clava, effectively kill Gram-positive bacteria at micromolar concentrations by permeabilizing their cytoplasmic membranes. The diversity of invertebrate AMPs reflects hundreds of millions of years of evolutionary arms races with marine pathogens.
Galendi et al. (2026) used proteomic analysis to identify antimicrobial peptides from fisheries bycatch, turning waste material into a source of bioactive molecules. This approach has both pharmacological and sustainability value: it extracts useful compounds from organisms that would otherwise be discarded.[13]
Arenicin, a 21-residue peptide from the lugworm Arenicola marina, has a single disulfide bond (Cys3-Cys20) that forms a cyclic beta-sheet structure with molecular masses of 2758.3 and 2772.3 Da for arenicin-1 and arenicin-2 respectively. Salnikov et al. (2011) used oriented solid-state NMR to determine how arenicin aligns within bacterial membranes, revealing that it inserts at a specific angle relative to the membrane normal that maximizes disruption of the lipid bilayer. This structural insight, showing exactly how the peptide positions itself within the membrane, explains arenicin's broad-spectrum activity against both bacteria and fungi and provides a template for engineering synthetic variants with improved selectivity.[14]
The diversity of marine invertebrate AMP structures is staggering. Beta-hairpins (tachyplesin, polyphemusin), alpha-helical peptides (clavanins), cyclic beta-sheets (arenicin), and cysteine-rich peptides (pengonadins) represent fundamentally different architectural solutions to the same problem: killing bacteria while surviving in a microbially dense aquatic environment. Each structural class offers a distinct starting point for drug design, and the marine environment has barely been surveyed. Current estimates suggest that over 90% of marine microbial species have never been cultured in a laboratory.
How Marine AMPs Kill: Beyond Pore Formation
The textbook mechanism for antimicrobial peptides is membrane disruption: the cationic peptide binds to the anionic bacterial membrane and forms pores that cause the cell to leak and die. Marine AMPs have revealed that the story is more complex than pore-punching alone.
Beyer et al. (2026) discovered that marine-inspired peptides L3 and L3-K, derived from genome mining of Streptomyces sp. H-KF8, kill uropathogenic Escherichia coli by disrupting gene expression at the DNA level. These peptides are serum-stable and noncytotoxic to mammalian cells, yet lethal to bacteria through a mechanism that does not involve membrane lysis. This finding opens a new category of antimicrobial action for marine-derived peptides: intracellular targeting of nucleic acid processes.[15]
Gao et al. (2025) described multiple mechanisms by which marine AMPs combat bacteria: direct membrane disruption, biofilm inhibition, quorum sensing interference (disrupting bacterial communication), and synergistic action with conventional antibiotics. Some marine AMPs kill bacteria at early stages of biofilm formation, while others penetrate established biofilms by degrading the extracellular matrix that protects bacterial colonies.[1]
The multimechanistic action of marine AMPs is their key advantage over conventional antibiotics. When a peptide attacks bacteria through three or four simultaneous mechanisms (membrane disruption, DNA binding, biofilm degradation, immune activation), the probability that bacteria evolve resistance to all mechanisms simultaneously is vanishingly small. This is why AMPs have remained effective for hundreds of millions of years while conventional antibiotics lose efficacy within decades. For deeper analysis of membrane disruption mechanisms, see our article on how antimicrobial peptides kill bacteria. For the broader case for AMPs replacing conventional antibiotics, see antimicrobial peptides as alternatives to antibiotics.
Marine AMPs Against Drug-Resistant Bacteria
The AMR crisis is the primary driver of marine AMP research. Methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and carbapenem-resistant Enterobacteriaceae pose immediate clinical threats that the current antibiotic pipeline cannot adequately address.
Li et al. (2026) showed that marine peptide N6NH2 and its D-enantiomer combated MDR Aeromonas veronii infection in tilapia. The dual antibacterial-immunomodulatory mechanism is particularly valuable against resistant strains: the peptide kills bacteria directly while simultaneously boosting the host immune response, creating a two-front attack that resistant bacteria cannot easily evade.[9]
Selvaraj et al. (2026) positioned marine-derived AMPs as "blue biotechnological assets for sustainable healthcare," arguing that the structural diversity of marine peptides provides a renewable pipeline of antimicrobial candidates. The AMR crisis demands not just one new drug but an ongoing stream of structurally novel compounds that bacteria have not previously encountered.[3]
The salt tolerance issue deserves emphasis here. Hospital wound infections occur in physiological saline environments. An AMP that works in a low-salt laboratory buffer but fails at 150 mM NaCl is clinically useless. Marine AMPs, evolved in seawater at approximately 500 mM NaCl, maintain activity at physiological salt concentrations where many terrestrial AMPs lose potency.[2]
Human defensins, the body's own antimicrobial peptides, face similar challenges. For how endogenous AMPs like LL-37 and defensins complement marine AMP research, see those articles. For the role of gut bacteria in producing their own antimicrobial peptides, see bacteriocins.
Beyond Antimicrobial: Anticancer and Anti-Aging Marine Peptides
Marine AMPs increasingly show activity against cancer cells. The selectivity principle is similar to antibacterial action: cancer cells often have more negatively charged membranes than healthy cells, making them preferential targets for cationic peptides.
Mohd Noordin et al. (2026) reviewed fish-derived AMPs as anticancer agents, documenting in vitro evidence that peptides originally identified for their antibacterial properties also kill tumor cells. The dual antimicrobial-anticancer activity is not coincidental. Both bacteria and cancer cells present anionic surface molecules (phosphatidylserine in cancer cells, lipopolysaccharide in Gram-negative bacteria) that attract cationic AMPs.[16]
Yao et al. (2024) reviewed marine peptides as anti-aging agents, covering their preparation, characterization, and mechanisms of action. Marine-derived peptides show antioxidant activity (scavenging free radicals), collagen-promoting effects, and photoprotective properties. The review documented peptides from fish, algae, sea cucumbers, and crustaceans with demonstrated anti-aging activity in both cell culture and animal models.[17]
Jo et al. (2024) surveyed marine peptides that inhibit angiotensin I-converting enzyme (ACE), a target for blood pressure reduction. These ACE-inhibitory peptides, derived from fish, mollusks, and algae, represent a food-pharmaceutical bridge: bioactive peptides that occur naturally in seafood and can be concentrated through hydrolysis and purification. Marine sources are considered excellent for bioactive peptide discovery due to their large structural diversity, low molecular weight, and high specificity for biological targets.[18]
The multifunctionality of marine peptides creates an interesting drug development question: should these molecules be developed as narrow-spectrum antimicrobials, or as broad-activity therapeutics that simultaneously fight infection, reduce inflammation, and kill cancer cells? The answer likely depends on the specific peptide and clinical context, but the inherent multifunctionality of marine AMPs is a feature, not a complication, for conditions where infection and inflammation coexist (such as chronic wounds and post-surgical infections).
From Discovery to Drug: The Manufacturing Challenge
The gap between identifying a promising marine AMP and producing it as a pharmaceutical product is substantial. Most marine organisms produce peptides in microgram quantities, far below the grams-to-kilograms needed for clinical development.
Dong et al. (2025) addressed this directly by developing a multicopy expression system for the marine AMP Spgillcin177-189 in Pichia pastoris yeast. The multicopy strategy inserts multiple copies of the peptide gene into the yeast genome, increasing expression levels compared to single-copy approaches. The recombinant peptide retained strong activity against S. aureus, demonstrating that yeast-produced marine AMPs can be functionally equivalent to native peptides.[11]
Chemical synthesis is an alternative for short peptides (under 40 amino acids) but becomes prohibitively expensive for longer sequences or those with complex post-translational modifications. Solid-phase peptide synthesis can produce marine AMPs at research scale, and modifications like D-amino acid substitution or cyclization can enhance stability for clinical use. For how synthetic AMP design builds on natural marine templates, see that dedicated article.
Several practical barriers remain between marine AMP discovery and clinical approval:
Toxicity. Many marine AMPs that kill bacteria also damage mammalian cells at similar concentrations. The therapeutic index (ratio of toxic dose to effective dose) must be widened through structural modification before clinical testing.
Stability. Even salt-tolerant marine AMPs can be degraded by mammalian proteases in blood and tissues. D-amino acid substitution, cyclization, and PEGylation are common strategies for extending half-life, but each modification risks altering the peptide's antimicrobial mechanism.
Spectrum. Some marine AMPs have narrow spectra, effective against specific bacterial strains but not others. Clinical antibiotics need predictable activity across pathogen types, which requires either broad-spectrum candidates or diagnostic-guided precision therapy. Conversely, AMPs that are too broad in their membrane-disrupting activity may damage beneficial microbiota alongside pathogens, a concern shared with broad-spectrum conventional antibiotics.
Regulatory pathway. AMPs are complex molecules that do not fit neatly into traditional small-molecule drug regulatory frameworks. Characterizing their mechanism of action, resistance potential, and safety profile requires specialized approaches that add time and cost to development.
Despite these barriers, the pace of marine AMP discovery is accelerating. Genome mining, deep learning algorithms, and high-throughput screening of marine microbiome libraries are expanding the candidate pool faster than traditional isolation methods ever could. Fan et al. (2024) constructed a bank of 713 culturable marine biofilm bacteria strains, mining their genomes to identify over 300 candidate antimicrobial peptides using ribosome profiling and deep learning prediction. This single study produced more candidates than decades of traditional isolation work.[1]
The Antimicrobial Peptide Database (APD) catalogues thousands of known AMPs, and marine-derived sequences represent one of the fastest-growing categories. Wang et al. (2026) described APD6, the latest expansion of this database, which deploys machine learning to predict peptide activity and guide rational design of new antimicrobial candidates.[1]
The convergence of marine biology, genomics, artificial intelligence, and peptide engineering is creating a discovery pipeline that would have been unimaginable a decade ago. The ocean's pharmacy is vast and largely unstocked on our shelves. The question is no longer whether marine AMPs can fight drug-resistant infections, but how quickly they can be manufactured, tested, and approved.
The Bottom Line
Marine organisms have produced antimicrobial peptides for hundreds of millions of years, creating a structural diversity that land-based organisms cannot match. Horseshoe crab tachyplesins, shrimp pengonadins, fish-derived dual-function peptides, and marine bacteria-inspired DNA-targeting molecules represent distinct chemical classes with distinct mechanisms of action. Over 70 are in drug development. The manufacturing, stability, and toxicity challenges that separate a promising peptide from an approved drug remain substantial, but the AMR crisis has made solving those problems urgent.